drugset
drugset / Trial / NCT01113463

TPI 287 in Patients With Recurrent Glioblastoma Multiforme

NCT01113463 ↗

Phase 2 Terminated 17 enrolled M.D. Anderson Cancer Center Cortice Biosciences, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if TPI 287 can help to control glioblastoma. The safety of this drug will also be studied.

Timeline

Start
2010-04
Primary completion
2011-06
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject TPI 287 Small molecule 160 mg/m2 Intravenous

Indications

brain cancer